Takeda Launches New Subsidiary in Peru

Zurich (ots/PRNewswire) -

Demonstrates Takeda's long-term commitment to the Latin American
market

Takeda Pharmaceuticals International GmbH ("Takeda") today announced
further expansion of its presence in Latin America with the launch of
a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. (Takeda Peru or
"the Company") will be headquartered in Lima and will be responsible
for the sales and marketing of Takeda's products in Peru.

Takeda is building a leading position in Latin America. It has a
direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia,
Ecuador and now Peru, and is looking at opportunities to further
expand its footprint in the region. According to IMS Market
Prognosis, pharmaceutical sales in those countries totaled US$60
billion in 2012 and are expected to grow at a compound annual rate of
12.5%* between 2013 and 2017. Takeda plans to outgrow the market over
the same period.

Peru is a dynamic and growing market, driven by government investment
and strong mining industries. It is estimated that the country's GDP
totaled US$ 200 billion in 2012 while pharmaceutical sales amounted
to US$1.5 billion and are expected to continue to grow by 8% during
2013*.

In line with Takeda's emerging markets strategy, Takeda Peru is
building a product portfolio based on the medical needs of the
population, focusing on gastroenterology, cardiology, metabolism,
oncology and respiratory diseases. The Company will initially focus
on Zurcal (pantoprazole), Riopan (Magaldrate + Dimeticone) Faktu
(Policresulen, Cinchocaine hydrochloride), and its gynaecology
product, Albothyl (Policresulen), which Takeda repatriated following
the Nycomed acquisition.

Takeda plans to leverage its Peru sales platform with a steady stream
of product launches from its existing portfolio and R&D pipeline.

Julio Cesar Acevedo Orrego has been appointed country manager for
Peru. He joins the organization from Takeda Colombia, where he has
built up and headed the Takeda Sales and Marketing organization
following the acquisition of Farmacol Laboratories. He will lead the
start-up team which will grow steadily as the Company expands its
portfolio and enters new therapeutic areas.

"The launch of our subsidiary in Peru reinforces Takeda's position in
Latin America and will enable us to meet the diverse healthcare needs
of the population. We have an established product portfolio, which
will give us a strong starting point and we look forward to launching
our novel medicines into the market," said Norbert Oppitz, Senior
Vice President, Latin America, at Takeda. "This investment further
demonstrates our commitment to Latin America and its growth
potential."

[*]Data Source?(c) 2012 IMS Health. All rights reserved. Estimate
based on Market Prognosis Global 2012-2016.

About Takeda Pharmaceuticals International GmbH

Headquartered in Zurich as a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, Osaka, Japan, the company has a
commercial presence covering more than 70 countries, with particular
strength in Asia, North America, Europe and fast-growing emerging
markets including Latin America, Russia-CIS and China. Areas of focus
include cardiovascular and metabolic, oncology, respiratory and
immunology, central nervous system, general medicine, and vaccines.

Takeda is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and
one of the global leaders of the industry, Takeda is committed to
strive towards better health for people worldwide through leading
innovation in medicine. Through the integration of Millennium
Pharmaceuticals and Nycomed, Takeda has been transforming itself,
broadening its therapeutic expertise and geographic outreach.

Additional information about Takeda is available through its
corporate website, http://www.takeda.com.

This press release has been issued by Takeda Pharmaceuticals
International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon,
Zurich, Switzerland.

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print